Table 1.
Clinical and demographic characteristics of patients who developed pulmonary NTM disease during biological therapy for RA
| Case no. | Age (years)/sex | BMI | RA duration (years) | RA activity | Stage | Treatment for RA (duration) a | Lung disease |
|---|---|---|---|---|---|---|---|
| 1 | 70/F | 21.2 | 21 | Low | IV | TCZ (4 m), IFX (6 m), MTX (3 years), PSL (18 m) | IP, BE |
| 2 | 62/F | 16.7 | 26 | >Moderate | III | ADM (10 m), PSL (8 years), TAC (2.5 years), SASP (8 years) | IP |
| 3 | 71/F | 21.1 | 19 | Remission | II | TCZ (8.5 years), PSL (>10 years) | None |
| 4 | 72/F | 16.4 | 14 | >Moderate | IV | ETN (11 m), PSL (9 years), SASP (11 years) | BE |
| 5 | 66/F | 21.1 | 16 | >Moderate | III | ETN (31 m), PSL (5 years), MTX (3 years), BUC (1 year), SASP (1 year) | None |
| 6 | 66/F | 21.5 | 24 | >Moderate | IV | IFX (6 w), PSL (10 m), MTX (18 m) | None |
| 7 | 62/F | 21.5 | 22 | Remission | IV | ETN (23 m), IFX (5 m), PSL (>10 years), SASP (>10 years) | IP |
| 8 | 81/F | 16.1 | 8 | Low | IV | ETN (10 m) | BE |
| 9 | 68/F | 23.7 | 2 | ND | II | ETN (11 m), PSL (22 m), MTX (1 m), SASP (2 m) | IP, BE |
| 10 | 58/F | 19.4 | 25 | >Moderate | IV | ADM (3 m), IFX (30 m), PSL, MTX, SASP | None |
| 11 | 63/F | 20.8 | 17 | Low | IV | ETN (2 m), PSL (9 years), MTX (4 years), SASP | None |
| 12 | 65/F | 15.2 | 30 | >Moderate | III | TCZ (3 m), PSL (14 years), BUC (7 years) | NTMb |
| 13 | 78/M | 17.2 | 10 | Low | III | TCZ (3 m), IFX (9 m), ETN (6 m), PSL (7 years), MTX (7 years), TAC (16 m), BUC (20 m), SASP (4 years), LEF (2 m) | BE, NTMb |
RA rheumatoid arthritis, NTM nontuberculous mycobacteria, BMI body mass index, TCZ tocilizumab, IFX infliximab, ADM adalimumab, ETN etanercept, MTX methotrexate, SASP salazosulfapyridine, BUC bucillamine, TAC tacrolimus, LEF leflunomide, PSL prednisolone, IP interstitial pneumonia, BE bronchiectasis, ND no data, m months, w weeks
aUnderlines indicate anti-RA drugs that were being used at the time of development of NTM disease, and the duration of therapy with these drugs represents the interval between the development of NTM disease and the introduction of the anti-RA drug(s) being used at that time. The drugs without underlines were no longer used at the time of development of NTM disease, and the duration for these agents represents the duration of their previous use
bThese patients had received appropriate anti-NTM therapy for the previous occurrences of NTM disease